Table 2. Variables related with the evolution of disease activity in patients with Early Arthritis.
| Model 1 | Model 2 | |||
| β Coeff. [95% CI] | p | β Coeff. [95% CI] | P | |
| Female gender | 1.0 [0.66–1.46] | <0.001 | 1 [0.6–1.3] | <0.001 |
| Age at DO (by 10 year) | 0.3 [0.2–0.4] | <0.001 | 0.3 [0.1–0.4] | <0.001 |
| RF Positive | - | n.s. | - | n.s. |
| ACPA Positive | 0.34 [0.01–0.67] | 0.044 | - | n.s. |
| IL-15 (by 20 pg/ml) | 0.12 [0.06–0.18] | <0.001 | 0.08 [0.02–0.14] | 0.003 |
| Methotrexate | −0.74 [−0.96–−0.52] | <0.001 | n.i. | - |
| Antimalarial | −0.48 [−0.79–−0.18] | 0.002 | n.i. | - |
| Sulphasalazine | - | n.s. | n.i. | - |
| Leflunomide | −0.52 [−0.9–−0.14] | 0.007 | n.i. | - |
| Cyclosporine A | - | n.s. | n.i. | - |
| Gold salts | - | n.s. | n.i. | - |
| TNF blockers | −1.33 [−2.08–−0.57] | 0.001 | n.i. | - |
Coeff: coefficient; CI: confidence interval; DO: disease onset; RF: rheumatoid factor; ACPA: anti-cyclic citrullinated peptide antibodies; n.s.: not significant; n.i.: not included. Multivariable analysis model 1 includes the effect of DMARD treatment at each visit whereas in model 2, the treatment was not considered.